Wedbush Initiates Coverage on Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX)

Investment analysts at Wedbush started coverage on shares of Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) in a research note issued on Thursday, Marketbeat Ratings reports. The brokerage set an “outperform” rating and a $22.00 price target on the stock. Wedbush’s price target would suggest a potential upside of 25.86% from the stock’s current price.

Separately, William Blair restated an “outperform” rating on shares of Telix Pharmaceuticals Limited American Depositary Shares in a research report on Wednesday, March 12th.

Telix Pharmaceuticals Limited American Depositary Shares Price Performance

Shares of NASDAQ TLX opened at $17.48 on Thursday. Telix Pharmaceuticals Limited American Depositary Shares has a 1-year low of $13.61 and a 1-year high of $30.36. The stock’s 50-day moving average is $16.75 and its 200 day moving average is $16.81.

Institutional Investors Weigh In On Telix Pharmaceuticals Limited American Depositary Shares

An institutional investor recently bought a new position in Telix Pharmaceuticals Limited American Depositary Shares stock. ABC Arbitrage SA acquired a new stake in shares of Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 26,939 shares of the company’s stock, valued at approximately $451,000.

About Telix Pharmaceuticals Limited American Depositary Shares

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.